This episode examines immunosuppressants and tolerogens as instruments of intentional restraint. When immune activation becomes misdirected—against self, grafts, or chronic inflammation—therapy aims not to erase immunity, but to recalibrate it. We explore how different classes intervene at distinct checkpoints of immune activation, why timing and combinations matter, and how risk is managed rather than eliminated.

Key takeaways you’ll build and reuse throughout the series:

* Immune checkpoints as targets: antigen presentation, lymphocyte activation, proliferation, and effector function.

* Classes with character: corticosteroids, calcineurin inhibitors, antimetabolites, mTOR inhibitors, and biologics as different modes of restraint.

* Tolerance versus suppression: inducing selective unresponsiveness rather than global shutdown.

* Predictable risks: infection, malignancy, metabolic effects—understood as extensions of mechanism.

* Clinical judgement: tailoring intensity to indication (transplant, autoimmunity, inflammation) and patient vulnerability.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe